Skip to content

13F-HR filed by VHCP Management III, LLC

VHCP Management III, LLC filed this 13F-HR for the quarter ended 2019-12-31, filed 2020-02-13, with 18 holding rows worth $503,631,000.

Accession
0000950123-20-001882
Filed
2020-02-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2019

A holdings report, 18 entries on the cover page, a total value of $503,631,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $503,631,000 with VALUE read as thousands by filing date, 13F file number 028-18930. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AXSOME THERAPEUTICS INC. COM05464T104Stock1,547,994$160,001,000thousands by filing date
CONSTELLATION PHARMACEUTICALS INC.210373106Common Stock2,516,242$118,540,000thousands by filing date
Milestone Pharmaceuticals Inc59935V107COM2,066,529$33,085,000thousands by filing date
RELMADA THERAPEUTICS INC75955J402COMMON STOCK767,938$29,950,000thousands by filing date
89BIO INC282559103COM958,765$25,206,000thousands by filing date
10X GENOMICS INC CL A COM88025U109Stock300,000$22,875,000thousands by filing date
FORTY SEVEN INC34983P104COM516,381$20,330,000thousands by filing date
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK575,000$19,728,000thousands by filing date
IVERIC BIO INC46583P102COM1,699,797$14,584,000thousands by filing date
KALVISTA PHARMACEUTICALS INC483497103COM619,905$11,041,000thousands by filing date
Adverum Biotechnologies, Inc.00773U108Common Stock946,234$10,901,000thousands by filing date
MARINUS PHARMACEUTICALS INC56854Q101COM5,016,164$10,835,000thousands by filing date
Mersana Therapeutics Inc59045L106Common Stock1,561,389$8,947,000thousands by filing date
MYOVANT SCIENCES LTDG637AM102COMMON STOCK-FO455,255$7,066,000thousands by filing date
NEXTCURE INC65343E108COM119,693$6,742,000thousands by filing date
ObsEva SAH5861P103COM810,264$3,095,000thousands by filing date
PROTAGONIST THERAPEUTICS74366E102COM80,929$571,000thousands by filing date
BELLEROPHON THERAPEUTICS INC078771102COM383,955$134,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-20-001882this filing2020-02-13acceptance time not in the bulk data set